According to Actover pharmaceutical group’s public relations, Dr. Babak Sharif Kashani, the president of the 8th International Heart Failure Congress of Iran, mentioned that the aim of this congress was to enhance the knowledge and awareness of colleagues and introduce modern diagnostic and therapeutic methods in the field of heart failure.

Dr. Sharif Kashani emphasized that this congress was focused on the prevention of heart failure and stated:

 “The heart failure pandemic is such that one-quarter of the global population may develop this disease during their lifetime. Therefore, understanding preventive methods for this deadly disease is extremely important.”  

He added that public awareness about heart failure is inadequate, noting that most patients with this condition do not follow their treatment plan diligently.
According to this cardiovascular specialist, individuals suffering from heart failure experience symptoms such as shortness of breath, fatigue, swollen legs, and fluid buildup around the heart and lungs, which necessitates timely medical intervention to prevent life-threatening consequences.
Dr. Sharif Kashani also announced the organization of specialized panels and discussions related to risk factors of the disease, such as proper lifestyle, avoiding smoking, controlling blood sugar, cholesterol, and blood pressure, during the 8th International Heart Failure Congress. This congress emphasizes the need for public awareness regarding the disease so that individuals understand the importance of consulting a doctor if they notice symptoms of heart failure.

Overview of Actover Pharmaceutical’s Cardiovascular Drugs at the 8th International Heart Failure Congress

With over half a century of experience and using the latest drug production technologies, Actover Pharmaceutical offers more than 300 pharmaceutical products across 15 therapeutic areas, with cardiovascular drugs making up a significant portion of its production portfolio.

Lepixa (Apixaban)

Apixaban, marketed under the brand name Lepixa, is produced by Actover Pharmaceutical. It is an anticoagulant drug classified as a direct oral anticoagulant. This drug works by inhibiting Factor Xa in the coagulation cascade, reducing the blood’s tendency to form clots.

Ticora (Ticagrelor)

Ticagrelor, marketed under the brand name Ticora by Actover Pharmaceutical, is a medication that reduces mortality from cardiovascular events, including heart attacks and strokes, and reduces clot formation on stents in patients with acute myocardial infarction.

Zyllt (Clopidogrel)

Zyllt is the brand name for Clopidogrel, produced by Actover Pharmaceutical under license from KRKA, Slovenia.
Zyllt (Clopidogrel) belongs to the antiplatelet drug category. It reduces and prevents platelet aggregation, thereby preventing the formation of blood clots.

Rytcard (Flecainide Acetate)

Rytcard is the brand name for Flecainide Acetate, produced by Actover Pharmaceutical. This drug is used to treat certain types of irregular heartbeats.

Clotover (Rivaroxaban)

Clotover is the brand name for Rivaroxaban, produced by Actover Pharmaceutical.
Rivaroxaban is an anticoagulant belonging to the direct oral anticoagulant class. This drug works by inhibiting Factor Xa in the coagulation cascade, reducing the blood’s tendency to form clots.

Bitval (Sacubitril/Valsartan)

Bitval is the brand name for a combination of two blood pressure-controlling drugs, Sacubitril and Valsartan, which is used for the treatment of heart failure. It is produced by Actover Pharmaceutical.

Rosurexin (Rosuvastatin)

Rosuvastatin, marketed under the brand name Rosurexin and produced by Actover Pharmaceutical, is a lipid-lowering drug.

TELMYC_H (Telmisartan_Hydrochlorothiazide)

TELMYC_H is the brand name for the Telmisartan_Hydrochlorothiazide combination drug produced by Actover Pharmaceutical, which is used for the treatment of high blood pressure.

Croszet (Ezetimibe/Rosuvastatin)

Croszet is the brand name for the Ezetimibe/Rosuvastatin combination drug produced by Actover Pharmaceutical, which is used as a lipid-lowering medication.

Valosap (Amlodipine/Valsartan)

Valosap is the brand name for the combination drug Amlodipine and Valsartan, produced by Actover Pharmaceutical.
Valosap is a combination of a calcium channel blocker and an angiotensin II receptor blocker and belongs to the class of antihypertensive drugs.

Metazero (Metoprolol Succinate)

Metazero is the brand name for the drug Metoprolol Succinate, produced by Actover Pharmaceutical under the license of KRKA Slovenia.
Metazero is a drug used for angina and hypertension and belongs to the class of beta-receptor blockers (selective beta-1 blocker).

Eprinsa (Eplerenone)

Eprinsa is the brand name for the drug Eplerenone, produced by Actover Pharmaceutical, and is prescribed for the treatment of heart failure.
Eplerenone is an aldosterone antagonist that reduces the retention of water and sodium in the body, and as a result, lowers blood pressure, helping to prevent strokes, heart attacks, and kidney complications.

Irbesal (Irbesartan)

Irbesal is the brand name for the drug Irbesartan produced by Actover Pharmaceutical. It is an antihypertensive medication from the class of angiotensin II receptor blockers.

Ralyza (Ranolazine)

Ralyza is the brand name for the drug Ranolazine, produced by Actover Pharmaceutical.
Ralyza is a medication for angina and helps alleviate chest pain for a long period of time.